

## Appendix 1: Supplementary resources for clinicians

US Centers for Disease Control and Prevention (CDC):

- Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. *MMWR Morb Mortal Wkly Rep* 2011;60:65-8. Available: [www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm)
- Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. *MMWR Morb Mortal Wkly Rep* 2012;61:586-9. Available: [www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a2.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a2.htm)

Ministère de la Santé et des Services sociaux. Avis intérimaire sur la prophylaxie préexposition au virus de l'immunodéficience humaine. 2013. Available: <http://publications.msss.gouv.qc.ca/acrobat/f/documentation/2013/13-308-03W.pdf>

Canadian Public Health Association HIV Portal: Preexposure Prophylaxis  
[www.cpha.ca/en/programs/portals/hiv/prevention/n3.aspx](http://www.cpha.ca/en/programs/portals/hiv/prevention/n3.aspx)

## Annotated bibliography

Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: Where have we been and where are we going? *J Acquir Immune Defic Syndr* 2013;63(Suppl 2):S122-9.

- This excellent review article describes the findings of major PrEP trials, outlines several demonstration projects that are currently under way, and describes priority questions for PrEP implementation.

Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med* 2012;367:411-22.

- This paper reports data from the Fem-PrEP trial among HIV-negative women in Kenya, South Africa, and Tanzania, where oral TDF/FTC was found to be ineffective, driven primarily by low adherence.

Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections 2013. Abstract 26LB.

- This abstract reports data from the VOICE trial among HIV-negative women in Uganda, South Africa and Zimbabwe, which was halted early because of poor efficacy for both topical tenofovir gel and oral TDF or TDF/FTC. This was primarily driven by poor adherence.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science* 2010;329:1168-74.

- This paper reports data from the CAPRISA-004 trial demonstrating adherence-dependent efficacy of tenofovir gel in HIV prevention among HIV-negative women in South Africa. This gel is not currently available for use outside of research settings.

van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. *AIDS* 2012;26:F13-9.

- This excellent article summarizes the key explanations for the divergent results from various PrEP trials, highlighting the role of adherence in determining PrEP efficacy.